TSTEM样CAR-T细胞在临床前模型中较传统CAR-T细胞表现出更好的持久性和肿瘤控制
研究发现在一项测试Lewis Y-CAR-T细胞的1期临床试验(NCT03851146)中,输注的CAR-T细胞产品中TSTEM细胞较少且持久性差。研究者开发了一种生产方案,生成富集细胞复制通路基因表达的TSTEM样CAR-T细胞,其在体外和临床前模型中表现出增强的增殖能力、细胞因子分泌、更好的肿瘤控制和持久性,并与抗PD-1治疗联用可根除已建立的肿瘤。
要点
- 1期试验(NCT03851146)中输注的Lewis Y-CAR-T细胞产品TSTEM细胞较少且持久性差。
- 新方案生成的TSTEM样CAR-T细胞体外增殖和细胞因子分泌增强,依赖生产过程中CD4+ T细胞的存在。
- 临床前模型中TSTEM样CAR-T细胞过继转移可更好控制已建立肿瘤并抵抗肿瘤再攻击,与持久性和记忆T细胞池增加相关。
核心结论
- CAR-T细胞生产方案生成的TSTEM样CAR-T细胞具有增强的治疗效力,在体内增殖能力和持久性增加。
研究设计与样本
- 临床前研究,包括体外实验和动物模型,并引用一项测试Lewis Y-CAR-T细胞的1期临床试验(NCT03851146)的观察。
主要发现
- 在1期临床试验(NCT03851146)中,输注的CAR-T细胞产品中TSTEM细胞较少,且输注的CAR-T细胞在患者中持久性差。
- 与传统CAR-T细胞相比,TSTEM样CAR-T细胞在CAR刺激后增殖能力增强、细胞因子分泌增加,包括体外慢性CAR刺激后。
- 这些反应依赖于TSTEM样CAR-T细胞生产过程中CD4+ T细胞的存在。
- 临床前模型中,TSTEM样CAR-T细胞过继转移诱导更好的已建立肿瘤控制和对肿瘤再攻击的抵抗,与TSTEM样CAR-T细胞持久性增加和记忆T细胞池增加相关。
- TSTEM样CAR-T细胞与抗程序性细胞死亡蛋白1(PD-1)治疗联用根除了已建立的肿瘤,与产生干扰素-γ的肿瘤浸润CD8+CAR+ T细胞增加相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients who receive chimeric antigen receptor (CAR)-T cells that are enriched in memory T cells exhibit better disease control as a result of increased expansion and persistence of the CAR-T cells. Human memory T cells include stem-like CD8+ memory T cell progenitors that can become either functional stem-like T (TSTEM) cells or dysfunctional T progenitor exhausted (TPEX) cells. To that end, we demonstrated that TSTEM cells were less abundant in infused CAR-T cell products in a phase 1 clinical trial testing Lewis Y-CAR-T cells (NCT03851146), and the infused CAR-T cells displayed poor persistence in patients. To address this issue, we developed a production protocol to generate TSTEM-like CAR-T cells enriched for expression of genes in cell replication pathways. Compared with conventional CAR-T cells, TSTEM-like CAR-T cells had enhanced proliferative capacity and increased cytokine secretion after CAR stimulation, including after chronic CAR stimulation in vitro. These responses were dependent on the presence of CD4+ T cells during TSTEM-like CAR-T cell production. Adoptive transfer of TSTEM-like CAR-T cells induced better control of established tumors and resistance to tumor rechallenge in preclinical models. These more favorable outcomes were associated with increased persistence of TSTEM-like CAR-T cells and an increased memory T cell pool. Last, TSTEM-like CAR-T cells and anti-programmed cell death protein 1 (PD-1) treatment eradicated established tumors, and this was associated with increased tumor-infiltrating CD8+CAR+ T cells producing interferon-γ. In conclusion, our CAR-T cell protocol generated TSTEM-like CAR-T cells with enhanced therapeutic efficacy, resulting in increased proliferative capacity and persistence in vivo.
引用
- Meyran D, Zhu JJ, Butler J, et al. TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. Sci Transl Med. 2023. PMID: 37018415. doi:10.1126/scitranslmed.abk1900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。